JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB320074

重组Anti SARS-CoV-2 Spike Glycoprotein S1 [Omi2-18]

Anti SARS-CoV-2 Spike Glycoprotein S1 [Omi2-18]

Be the first to review this product! Submit a review

|

(0 Publication)

Human Recombinant Monoclonal SPIKE antibody. Suitable for I-ELISA and reacts with SARS-CoV-2 samples.

查看别名

2, S, Spike glycoprotein, S glycoprotein, E2, Peplomer protein

1 Images
Indirect ELISA - Anti SARS-CoV-2 Spike Glycoprotein S1 [Omi2-18] (AB320074)
  • I-ELISA

Supplier Data

Indirect ELISA - Anti SARS-CoV-2 Spike Glycoprotein S1 [Omi2-18] (AB320074)

This data was developed using ab320075, the same antibody clone in a different buffer formulation. Indirect ELISA- Anti SARS-CoV-2 Spike Glycoprotein S1 [Omi2-18] Antibody (ab320075). Indirect ELISA showing primary antibody ab320075 binding to Recombinant SARS-CoV-2 Spike Trimer, His Tag, (B.1.1.529/Omicron) and SARS-CoV-2 Spike RBD, His Tag, (B.1.1.529/Omicron). Plates were coated with Recombinant SARS-CoV-2 Spike Trimer, His Tag, (B.1.1.529/Omicron), SARS-CoV-2 Spike RBD, His Tag, (B.1.1.529/Omicron) and Recombinant Human Coronavirus SARS-CoV-2 Spike Glycoprotein RBD (His tag), ab275986, (2019-nCoV, SARS-CoV-2) at 1000 ng/ml. Binding of ab320075 was assessed in a serial dilution range 0.016- 1000 ng/mL (a 3-fold serial dilution).

不同偶联物与剂型 (1)

  • Carrier free

    Anti SARS-CoV-2 Spike Glycoprotein S1 [Omi2-18] BSA and Azide Free

关键信息

宿主种属

Human

克隆

Monoclonal

克隆号

Omi2-18

亚型

IgG1

不含载体蛋白

No

反应种属

SARS-CoV-2

应用

I-ELISA

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IELISA" : {"fullname" : "Indirect ELISA", "shortname":"I-ELISA"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "SARS-CoV-2": { "IELISA-species-checked": "testedAndGuaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "<p></p>" } } }

产品详情

Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

性能和储存信息

形式
Liquid
纯化工艺
Affinity purification Protein A
存储溶液
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
运输条件
Blue Ice
推荐的短期储存时间
1-2 weeks
推荐的短期储存条件
+4°C
推荐的长期储存条件
-20°C
分装信息
Upon delivery aliquot
储存信息
Avoid freeze / thaw cycle

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

The SARS-CoV-2 Spike Glycoprotein also known as COVID-19 Spike Protein is a trimeric protein weighing approximately 180-200 kDa. It is located on the surface of the SARS-CoV-2 virus playing an important role in virus infectivity. The protein comprises two main subunits S1 and S2 which facilitate attachment to and fusion with host cells. The S1 subunit contains the receptor binding domain (RBD) which specifically binds to the human angiotensin-converting enzyme 2 (ACE2) receptor. The Spike Glycoprotein is expressed in infected host cells mainly in the respiratory tract allowing the virus to enter and initiate replication.
Biological function summary

The SARS-CoV-2 Spike Glycoprotein initiates viral entry by interacting with the host cell's ACE2 receptor which leads to viral fusion and entry into the cell's cytoplasm. The protein is part of the virion structure and forms the visible spike on the virion's surface. Upon binding a conformational change triggers the fusion of viral and cellular membranes a vital step for the viral lifecycle. The multimeric nature of the Spike Protein facilitates its interaction with antibodies including those known as 'anti-spike antibodies' which can neutralize the virus and prevent cell infection.

Pathways

The Spike Glycoprotein plays a significant role in the viral infection process and immune response pathways. It is central to the receptor-mediated endocytosis pathway where the virus is internalized into host cells. The protein’s interaction with ACE2 modifies downstream signaling pathways potentially altering host cell functions. Related proteins in these pathways include the ACE2 receptor and the cellular protease TMPRSS2 which primes the Spike Protein for fusion and viral entry.

The Spike Glycoprotein is chiefly implicated in COVID-19 the disease caused by SARS-CoV-2. The interaction with ACE2 is not just vital for infection but also contributes to the disease's symptomatology as ACE2 is involved in regulating blood pressure and inflammation. Additionally the Spike Protein's role in viral entry makes it a target for therapeutic interventions including 'anti-spike antibodies' and vaccines aimed at blocking this process to prevent infection. The protein's relevance to COVID-19 has led to significant interest in developing diagnostic and therapeutic tools such as 'antibodies COVID' that target the Spike Glycoprotein to manage the disease effectively.

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

靶点信息

Spike protein S1. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2 (PubMed : 32142651, PubMed : 32155444, PubMed : 33607086). When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane (PubMed : 34561887). When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis leading to fusion of the virion membrane with the host endosomal membrane (PubMed : 32075877, PubMed : 32221306). Alternatively, may use NRP1/NRP2 (PubMed : 33082294, PubMed : 33082293) and integrin as entry receptors (PubMed : 35150743). The use of NRP1/NRP2 receptors may explain the tropism of the virus in human olfactory epithelial cells, which express these molecules at high levels but ACE2 at low levels (PubMed : 33082293). The stalk domain of S contains three hinges, giving the head unexpected orientational freedom (PubMed : 32817270).. Spike protein S2. Precursor of the fusion protein processed in the biosynthesis of the S protein and the formation of virus particle. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains two viral fusion peptides that are unmasked after cleavage. The S2/S2' cleavage occurs during virus entry at the cell membrane by host TMPRSS2 (PubMed : 32142651) or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change leading to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.. Spike protein S2'. Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.
See full target information S

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com